Study guide

9.3 Generic Substitution & Interchangeable Biologics (§6816-a)

New York MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the NY MPJE Exam 1.2 Study Strategy & Federal vs. New York Law Hierarchy

2 Federal Pharmacy Law: Controlled Substances

2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Registration, Forms & Security 2.3 Federal Food, Drug, and Cosmetic Act (FDCA)

3 Federal Pharmacy Law: Privacy & Supply Chain

3.1 HIPAA & Patient Privacy 3.2 OBRA '90, Medicare/Medicaid & DUR 3.3 DSCSA & Drug Supply Chain Integrity

4 Area 1a: NYSED, Board & Pharmacist Licensure

4.1 NYSED Office of the Professions, Board of Pharmacy & Education Law Article 137 4.2 Pharmacist Licensure: Education, NAPLEX/MPJE & Internship 4.3 License by Endorsement, Renewal & Continuing Education

5 Area 1b: Interns, Technicians & Discipline

5.1 Pharmacy Interns & Limited Permits 5.2 Registered Pharmacy Technicians (RPhT) & Supervision Ratios 5.3 Professional Misconduct, Discipline & Impaired Practitioner Programs

6 Area 2a: Prescribing, Controlled Substances & Collaborative Practice

6.1 Prescription Requirements & Practitioner Authority 6.2 Controlled Substance Prescribing & the NY EPCS Mandate 6.3 Refills & Authority Limitations 6.4 Collaborative Drug Therapy Management (§6801-a) & Non-Patient-Specific Orders

7 Area 2b: Counseling, Immunization & Public Health

7.1 Patient Counseling & Documentation 7.2 Pharmacist Immunization Authority 7.3 Naloxone Access & Public Health Programs 7.4 Patient Confidentiality & Pharmacy Records

8 Area 3a: Verification, Transfers & DUR/I-STOP

8.1 Legitimate Medical Purpose & Corresponding Responsibility 8.2 Prescription Transfers Between Pharmacies 8.3 Prospective DUR & the I-STOP PMP Registry 8.4 Refill Exceptions & Emergency Dispensing

9 Area 3b: Labeling, Packaging & Substitution

9.1 Labeling of Dispensed Drugs 9.2 Packaging: PPPA & Child-Resistant Containers 9.3 Generic Substitution & Interchangeable Biologics (§6816-a) 9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales

10 Area 4a: Records, Inventories & Delivery

10.1 Ordering, Acquisition & Distribution Records 10.2 Recordkeeping, Storage & Handling 10.3 Controlled Substance Inventories & BNE Registration 10.4 Delivery & Mail-Order Dispensing

11 Area 4b: Compounding, Central Fill & Facilities

11.1 Compounding: Non-Sterile, Sterile & Hazardous Drugs 11.2 Central Fill, Centralized Processing & Shared Pharmacy Services 11.3 Automated Dispensing & Telepharmacy 11.4 Pharmacy Establishment Registration, Inspections & Discipline

12 Test-Day Strategy & Final Review

12.1 When New York Law Is Stricter Than Federal Law 12.2 Test-Day Strategy & Common Traps

9.3 Generic Substitution & Interchangeable Biologics (§6816-a)

Key Takeaways Explain This Topic AI

Education Law § 6816-a is titled "When Substitution Is Required" — a pharmacist SHALL substitute a less expensive, same-active-ingredient/dosage-form/strength drug product unless the prescriber prohibits it.

The substitute drug product must appear on the approved drug products list maintained under Public Health Law § 206.

Under § 6816-a(4), a pharmacist who substitutes an interchangeable biological product must communicate the specific product and manufacturer dispensed to the prescriber within 5 business days.

The pharmacist must label the dispensed product's actual name, strength, and manufacturer on the container unless the prescriber specifically states otherwise.

8 NYCRR § 29.7(a)(6) separately makes it unprofessional conduct to omit the manufacturer's name from the prescription and label when a generic or interchangeable biologic is dispensed.

Last updated: July 2026

Why § 6816-a Uses "Shall," Not "May"

Unlike states where generic substitution is purely discretionary, New York's substitution statute is captioned "When Substitution Is Required" — Education Law § 6816-a uses mandatory language: a pharmacist "shall substitute" a less expensive, therapeutically equivalent product whenever the statutory conditions are met. On the MPJE, an answer implying substitution is the pharmacist's optional courtesy is wrong for New York; substitution is a default duty that only an unambiguous prohibition can turn off.

The Drug-Product Substitution Rule — § 6816-a(1)

A pharmacist shall substitute a less expensive drug product containing the same active ingredient(s), dosage form, and strength as the product prescribed, ordered, or demanded, when all of the following are true:

The prescription form permits it. Written prescriptions must comply with Education Law § 6810(6)'s form requirements — meaning the prescriber has not marked the prescription to prohibit substitution. For an oral prescription, the prescriber must expressly state, at the time it is called in, whether substitution is permitted or prohibited.

The substitute is on the state's approved list. The substituted product must appear on the approved drug products list maintained under Public Health Law § 206 — New York's equivalent of an "AB-rated" formulary. A pharmacist may not substitute an off-list product no matter how similar it appears to the prescribed drug.

Labeling duty. The pharmacist must indicate on the label affixed to the immediate container the name and strength of the drug product actually dispensed and its manufacturer , unless the prescriber specifically states otherwise.

Recordkeeping duty. The prescription record itself must document the brand name or the manufacturer's name of the drug product dispensed , so the dispensing history is traceable back to the actual product given to the patient — not just the product originally written.

The Interchangeable Biological Product Rule — § 6816-a(3)–(4)

New York extends the same mandatory-substitution logic to interchangeable biological products — biologics the FDA has formally designated as interchangeable with a specific reference product (or with each other). Under § 6816-a(3), a pharmacist shall substitute a less expensive interchangeable biological product for the one prescribed when:

Condition Detail

FDA interchangeability The substitute is FDA-designated as interchangeable with the prescribed product, or the prescribed product is interchangeable with it

No prohibition The prescriber has not prohibited substitution

Labeling Same duty as drug products — label must show the dispensed biologic's name, strength, and manufacturer unless the prescriber states otherwise

Biologics carry one duty that drug-product substitution does not: prescriber notification . Under § 6816-a(4), within five business days of dispensing a substituted biological product, the dispensing pharmacist (or a designee) must communicate to the prescriber the specific product provided — name and manufacturer. This notice may go through an electronic records system the prescriber can access, a fax, or another electronic method; telephone communication is a fallback only when electronic means are not available. This added duty exists because interchangeable biologics, unlike small-molecule generics, are not always structurally identical to the reference product, so continuity-of-care tracking matters more.

Biosimilar vs. Interchangeable: Why the Distinction Drives § 6816-a

Not every biosimilar qualifies for pharmacy-level substitution under § 6816-a — only those the FDA has specifically designated interchangeable . Under the federal Biologics Price Competition and Innovation Act (BPCIA) framework, a biosimilar is a biologic shown to be highly similar to a reference product with no clinically meaningful differences in safety or effectiveness, but it still generally requires a new prescription to switch a patient onto it. An interchangeable biological product must clear a materially higher bar — including, where required, switching studies showing that alternating between the interchangeable product and its reference product does not increase safety or efficacy risk compared to using the reference product alone. Because only FDA-designated interchangeable products meet that higher bar, they are the only biologics § 6816-a authorizes a pharmacist to substitute at the counter without contacting the prescriber first; a merely "biosimilar" (but not interchangeable) product cannot be substituted under this statute even if it is clinically similar.

How the Prescriber Turns Off Substitution

A prescriber prohibits substitution by using the mechanism built into the prescription form under Education Law § 6810(6) (for written prescriptions) or by expressly stating "no substitution" at the time an oral prescription is called in. Silence on a properly formatted written prescription is not a prohibition — the statutory default is substitution.

Layered Discipline: § 29.7(a)(6)

As covered in § 9.1, 8 NYCRR § 29.7(a)(6) separately makes it unprofessional conduct to fail to write the manufacturer's (and distributor's, if different) name on both the prescription and the label when dispensing a generic or interchangeable biological product. This regulation and § 6816-a's labeling duty reinforce each other: the statute creates the substitution and labeling obligation, and the misconduct regulation is the Board's enforcement hook if a pharmacist skips it.

Common MPJE Traps

Treating New York generic substitution as optional or discretionary — it is a default duty , not a courtesy, once the statutory conditions are met.

Substituting a therapeutically similar but not Public Health Law § 206-listed product — off-list substitution is not authorized even when the active ingredient, dosage form, and strength all match.

Forgetting the 5-business-day prescriber notification for biologic substitutions — this duty does not exist for ordinary small-molecule generic drug substitution.

Assuming a phone call is always an acceptable way to notify the prescriber of a biologic substitution — it is the fallback method only when electronic communication is unavailable.